Elizabeth Koslosky's questions to Agilent Technologies Inc (A) leadership • Q2 2025
Question
Elizabeth Koslosky, on behalf of Matt Sykes at Goldman Sachs, asked about differing order patterns between clinical QA/QC and early research within pharma. She also inquired about the impact of potential changes in U.S. water regulations on the PFAS testing market.
Answer
CEO Padraig McDonnell highlighted that Agilent's pharma business is predominantly in the more resilient QA/QC and development space, with the small molecule segment growing a strong 10% in the quarter. Regarding PFAS, he noted exceptional 75% year-over-year growth and stated that future growth will be driven not just by water testing but also by industrial wastewater, material testing, and emerging air testing applications, mitigating risks from any single regulatory change.